Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Sheffield Medical Technologies and Alpha Therapeutic enter into option agreement

Nov. 1, 1996

Oncogene awarded drug discovery grant

Nov. 1, 1996

Lilly and Neurocrine collaborate in the areas of obesity and Alzheimer's disease

Nov. 1, 1996

Antiobesity proteins described by Lilly

Nov. 1, 1996

CRADA opportunity for the treatment of atherosclerosis and LCAT deficiency

Nov. 1, 1996

Mitsubishi to copromote OrthoLogic 1000 in Japan

Nov. 1, 1996

FCP-3P1 in Canadian clinical trials

Nov. 1, 1996

Canadian researchers claim hPTH analogues for osteoporosis

Nov. 1, 1996

Lilly continues to investigate new agents for women's health

Nov. 1, 1996

Theratechnologies-Beaufour Ipsen agreement on TH-9506

Oct. 25, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.